Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Leukemia and Lymphoma

Volumn 50, Issue 5, 2009, Pages 781-787

  Costa, Luciano J ^a   Kumar, Shaji ^b   Dispenzieri, Angela ^b   Hayman, Suzanne E ^b   Buadi, Francis K ^b   Dingli, David ^b   Litzow, Mark R ^b   Gertz, Morie A ^b   Lacy, Martha Q ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

Allografts; Graft versus host disease; Hematopoietic stem cell transplantation; Multiple myeloma

Indexed keywords

BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CONTROL; CANCER SURVIVAL; CANCER TRANSPLANTATION; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGE FACTORS; BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 68449088807     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902803644     Document Type: Article

References (22)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
4. Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007;13:925-931.
5. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. European group for bone marrow transplantation. N Engl J Med 1991;325:1267-1273.
6. Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. T-cell - depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versusmyeloma effect. Blood 2001;98:934-939.
7. Surveillance Epidemiology and End Results. National Cancer institute. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html. Cited 20 November 2008.
8. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001;113:209-216.
9. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: An analysis of prognostic factors from the chronic leukaemia working party of the EBMT. Blood 2005;105:4532-4539.
10. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002;30:367-373.
11. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110-1120.
12. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-3480.
13. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
14. Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, et al. Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005;128:496-502.
15. Bjorkstrand BB, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation. Blood 1996;88:4711-4718.
16. Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: Impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003; 32:1145-1151.
17. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502.
18. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441.
19. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793.
20. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008;83: 1131-1138.
21. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-5087.
22. Gahrton G, Iacobelli S, Bandini G, Bjorkstrand B, Corradini P, Crawley C, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007;92: 1513-1518.